Asset Details
Do you wish to reserve the book?
Drug Development
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Drug Development
Do you wish to request the book?
Drug Development
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Drug Development
2025
Overview
Temporal interference (TI) stimulation is a novel method of electrical brain stimulation that is capable of non-invasively and selectively targeting deep brain structures. Previously, we demonstrated that TI stimulation could modulate hippocampal activity and improve performance on an episodic memory task in healthy young adults. In this study, we investigated the effects of multi-session TI stimulation of the hippocampus in patients with early-stage Alzheimer's disease (AD).
Twenty-one AD patients received 50 minutes of TI stimulation to the left hippocampus daily, over 10 consecutive days. The effects of the intervention were assessed using a battery of neurocognitive assessments and neuroimaging measures, including positron emission tomography (PET) of mitochondrial complex-1, blood-oxygen level-dependent functional magnetic resonance imaging (BOLD fMRI), arterial spin labelling (ASL) and diffusion tensor imaging (DTI).
We demonstrate that multi-session TI stimulation of the hippocampus is safe and well-tolerated. Following TI stimulation, AD patients showed selective improvements in hippocampal-dependent episodic memory tasks.
We report the main outcomes in terms of safety, neurocognitive assessments and neuroimaging measures from the first study of TI stimulation in patients with early-stage AD.
